Bristol Myers Squibb posts higher first-quarter profit and revenue
Updated
Updated · The Wall Street Journal · Apr 30
Bristol Myers Squibb posts higher first-quarter profit and revenue
12 articles · Updated · The Wall Street Journal · Apr 30
Net income rose to $2.68bn, or $1.31 a share, on revenue of $11.49bn, while adjusted earnings of $1.58 a share beat FactSet forecasts.
Growth-portfolio sales climbed 12%, led by Camzyos, Breyanzi and Reblozyl, while legacy-portfolio revenue fell 6% amid generic competition despite higher Eliquis demand.
International sales increased 11% to $3.7bn as US sales slipped 1% to $7.8bn, and the drugmaker reaffirmed full-year guidance, saying results are trending toward the upper end.
Can Bristol Myers' new drugs outrun its looming multi-billion dollar patent cliff?
Did Medicare's price cut on the blood thinner Eliquis create a supply crisis?
With new FDA warnings, what are the hidden cancer risks of CAR T-cell therapies?